NALM-33 Xenograft Model Service for ALL

The NALM-33 cell line provides a highly specialized and translationally relevant in vivo platform for investigating B-cell precursor Acute lymphoblastic leukemia (ALL), specifically for evaluating novel targeted therapies in a physiologically complex model. As a premier pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision NALM-33 Xenograft Model Service, meticulously optimized to provide reproducible, audit-ready data packages that accelerate your ALL drug discovery and development pipeline.

Overview of NALM-33 Xenograft Model for ALL

The NALM-33 xenograft model is an established in vivo translational system widely utilized in hematological oncology research for the study of ALL. By transplanting human NALM-33 B-precursor cells into highly permissive, immunodeficient rodent hosts, this model effectively reproduces the systemic dissemination, bone marrow homing kinetics, and peripheral blood pathophysiological profiles characteristic of progressive human ALL.

Biologically, the NALM-33 model is highly valued for its consistent engraftment profiles and predictable disease progression, which provide investigators with a reliable experimental window for evaluating complex dosing schedules and pharmacodynamics. This model preserves critical human lymphoid molecular features, including lineage-specific marker expression (such as CD19 and CD22) and intracellular signaling pathways that drive malignant blast expansion. Consequently, the NALM-33 model is extensively deployed in pre-clinical screening programs to assess the anti-leukemic potency of novel small-molecule inhibitors, targeted monoclonal antibodies, and combination therapeutic regimens in a physiologically relevant in vivo setting.

Cell Line Information: NALM-33

The NALM-33 cell line is derived from the peripheral blood of a patient diagnosed with B-cell precursor ALL. These cells grow as suspension cultures under standard in vitro laboratory parameters, maintaining a stable lymphoblastoid phenotype that serves as a robust proxy for hematological cancer research.

Our Services

Workflow of NALM-33 Xenograft Model Construction

• Cell Culture & Quality Control: Human NALM-33 cells are expanded in vitro using certified nutrient suspension media under optimized growth parameters. STR authentication and mycoplasma clearance verification are completed prior to inoculation to ensure absolute phenotypic identity and biological purity.
• Host Selection & Acclimatization: Standardized, healthy immunodeficient mice (e.g., NSG or NOD/SCID strains to support hematological engraftment) are sourced from validated vendors. The animals undergo a dedicated acclimatization phase to stabilize baseline biological and physiological metrics.
• Precision Inoculation: A calibrated suspension of high-viability NALM-33 cells is prepared in a sterile physiological buffer. The cellular suspension is precisely inoculated in vivo into the host cohorts via tail vein intravenous routes to facilitate systemic leukemic distribution.
• Longitudinal Growth Tracking: Following inoculation, disease progression is systematically monitored using FACS to detect human CD45+ cells or specific lymphoid markers (such as CD19 or CD22) in peripheral blood. Animal weight, physical clinical indicators, and systemic disease burden are documented routinely.
• Stratification & Dosing: Once peripheral leukemic chimerism reaches a predetermined, statistically optimal range, the mice are randomized into matched experimental cohorts to ensure balanced baseline systemic dimensions before the initiation of customized therapeutic dosing regimens.

Fig 1. NALM-33 Xenograft Model Construction Workflow

Case Study - NALM-33 Xenograft Model Development

A pre-clinical validation study was conducted using the NALM-33 xenograft model to evaluate the therapeutic efficacy of a novel targeted inhibitor designed for ALL. Following precision intravenous inoculation of human NALM-33 cells into immunodeficient mice, the animals exhibited steady, systemic leukemic engraftment and highly predictable disease progression across all study cohorts. Animals assigned to the active treatment group demonstrated a clear, statistically significant reduction in circulating leukemic blasts and prolonged survival times compared to the vehicle control, confirming the model's high sensitivity and predictive reliability for screening targeted ALL therapies.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in managing diverse hematological and lymphoid lineages, providing highly reproducible in vivo translational platforms for complex leukemia research.
• Rigorous Quality Control: Meticulous cell validation and standardized operating procedures that minimize experimental variability across all project stages.
• Tailored Experimental Design: Highly flexible protocols that adapt to specific animal strain requirements, custom dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready report providing comprehensive FACS metrics and robust statistical validations.

Contact us

Accelerating your ALL pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our NALM-33 platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.